ADXS11-001 immunotherapy targeting HPV-E7: updated survival and safety data from a phase 2 study in Indian women with recurrent/refractory cervical cancer

Documenti analoghi

• ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
  di: Petit, Robert G, et al.
  Pubblicazione: (2014)
• A Randomized Phase 2 Study of ADXS11-001 Listeria monocytogenes–Listeriolysin O Immunotherapy With or Without Cisplatin in Treatment of Advanced Cervical Cancer
  di: Basu, Partha, et al.
  Pubblicazione: (2018)
• Biomarker identification in serum samples from patients with recurrent cervical cancer treated with ADXS11-001 immunotherapy
  di: Molli, Poonam, et al.
  Pubblicazione: (2013)
• Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer
  di: Cohen, Ezra EW, et al.
  Pubblicazione: (2015)
• Mechanistic insights into ADXS11-001 human papillomavirus-associated cancer immunotherapy
  di: Miles, Brett A., et al.
  Pubblicazione: (2017)